Document Reference: AHQ-WEB-EDU-OA-002 · Version 1.0 · March 2026 · For Review: March 2027
Clinical Education
Osteoarthritis & Regenerative Medicine in Australia
Aeterna Health Qld is the only commercial provider of hospital-delivered cellular therapy (commonly referred to as stem cell therapy) in Australia — positioning us as a uniquely compliant stem cell Australia provider.
Delivered under the clinical care of a registered medical practitioner, within an accredited hospital.
The Scale of the Challenge
Osteoarthritis (OA) is the most common form of arthritis and one of Australia’s most significant chronic health conditions.
Prevalence & Demographics
Prevalence increases sharply with age: 10% of Australians aged 45–54, rising to 30% aged 75 and over. Women are significantly more likely to be diagnosed than men across all joint types. People in regional Australia are more likely to have arthritis (19.9% vs 12.8% in major cities). The Global Burden of Disease Study 2019 estimated 3.20 million Australians had OA — with knee OA increasing 126%, hip OA 171%, and hand OA 110% since 1990.
Total Joint Replacement in Australia
Joint replacement surgery is currently the definitive surgical treatment for end-stage osteoarthritis. All data is drawn from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), with over 98% national coverage.
| Procedure (2022–2023) | Change |
|---|---|
| Total Hip Replacement | +9.1% |
| Total Knee Replacement | +19.2% |
| Total Shoulder Replacement | +13.9% |
| Combined (Hip, Knee, Shoulder) | 146,795 procedures, +16.0% |
| Procedure | 2013 Baseline | Projected 2030 | Increase |
|---|---|---|---|
| Total Knee Replacement (OA) | 42,920 | 161,231 | +276% |
| Total Hip Replacement (OA) | 25,945 | 79,795 | +208% |
Surgery is generally reserved for severe, end-stage OA where conservative management has failed. Joint replacement is irreversible, with recovery periods typically 6 weeks to 6 months. Younger patients face higher lifetime risk of requiring revision surgery. Growing waitlist pressures in the public system mean many patients face extended delays.
Platelet-Rich Plasma (PRP) for Osteoarthritis
PRP is an autologous blood product prepared by centrifuging a blood sample to concentrate platelets and associated growth factors. These components modulate local inflammation and stimulate tissue repair processes within the joint environment.
Current Evidence
A 2023 network meta-analysis of 35 RCTs involving over 3,100 patients ranked PRP as the most effective intra-articular injection intervention for knee OA. Evidence is strongest for mild to moderate knee OA (Kellgren–Lawrence grades I–III). Leukocyte-poor PRP generally demonstrates superior outcomes for OA. In Australia, PRP for musculoskeletal conditions is not listed on the Medicare Benefits Schedule and is accessed on a private-pay basis.
Autologous Cellular Therapies: SVF and MSCs
In Australia, autologous SVF derived from a patient’s own adipose tissue and used during the same surgical procedure, within an accredited hospital, is exempt from TGA therapeutic goods registration under the same surgical procedure exemption (TGA Risk Level 1). Any clinical application must be conducted within the appropriate regulatory and clinical governance framework.
What Is Stromal Vascular Fraction (SVF)?
SVF is a heterogeneous cell population derived from adipose (fat) tissue through a minimally invasive lipoaspiration procedure. It contains mesenchymal stem/stromal cells, endothelial progenitor cells, pericytes, immune-modulating cells, and pre-adipocytes. Adipose tissue yields considerably higher numbers of MSCs per unit volume compared to bone marrow and can be processed in the same surgical session.
Clinical Evidence for SVF
A 2025 systematic review found significant pain relief and joint function improvements up to 2–5 years post-SVF treatment, with minimal adverse reactions. A 2024 meta-analysis of 31 studies involving 1,406 patients found significant improvements in knee function, pain reduction, and cartilage repair outcomes. A multicentre study of 1,128 patients treated across 1,856 joints demonstrated safety and clinical improvement in a substantial majority of patients.
Comparison: PRP vs SVF vs Culture-Expanded MSCs
| Feature | PRP | SVF (Autologous) | Culture-Expanded MSCs |
|---|---|---|---|
| Source | Patient’s blood | Patient’s adipose tissue | Patient’s tissue, lab-expanded |
| Processing | Same-day centrifugation | Same-day enzymatic isolation | Laboratory expansion (weeks) |
| Australian regulatory status | Autologous blood product | TGA Risk Level 1 same surgical procedure exemption | Requires TGA oversight as biological medicine |
| Evidence for OA | Moderate — strongest for mild-moderate knee OA | Emerging — promising 2–5 year data | Growing — primarily clinical trial settings |
This comparison is educational in nature and is not intended as comparative therapeutic claims. Individual outcomes depend on many factors including OA severity, age, BMI, and clinical indication.
The Treatment Landscape
| Treatment | Typical OA Stage | Nature |
|---|---|---|
| Exercise, physiotherapy, weight management | All stages (first-line) | Non-invasive, conservative |
| NSAIDs / Analgesics | All stages | Pharmacological |
| Corticosteroid / HA injection | Mild–Moderate | Intra-articular, non-cellular |
| Platelet-Rich Plasma (PRP) | Mild–Moderate | Autologous blood product |
| Autologous SVF | Mild–Moderate | Autologous cellular, minimally invasive |
| Total Knee / Hip Replacement | Severe (end-stage) | Major surgery, definitive |
Treatment selection is always an individual clinical decision made by a qualified healthcare professional in consultation with the patient.
Australian Bureau of Statistics National Health Survey 2022; AIHW 2024; Global Burden of Disease Study 2019 (Ackerman et al., Internal Medicine Journal, 2023); AOANJRR Annual Report 2024; Ackerman et al., BMC Musculoskeletal Disorders, 2019; Ackerman et al., Lancet Regional Health, 2024; Konidaris et al., Journal of Clinical Medicine, 2025; Gao et al., Stem Cell Reviews and Reports, 2025; Lee et al., Stem Cell Research & Therapy, 2024.
Speak to Your Doctor About Your Options
If you believe regenerative medicine may be relevant to your situation, the right starting point is a conversation with your GP. They can assess your clinical history, current management, and whether a specialist referral is appropriate.
Educational resource. Does not constitute medical advice, a therapeutic claim, or a treatment recommendation. Document reference: AHQ-WEB-EDU-OA-002 Version 1.0, March 2026. Review due: March 2027.